S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. (23rd June 2022)

• Record Type: Journal Article
• Authors: Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Cohen, J. B.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C.; Lewis, D.; Gerson, J. N.; Alencar, A. J.; Ujjani, C.; Flinn, I.; Sundaram, S.; Ma, S.; Jagadeesh, D.; Rhodes, J.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Wang, D.; Nair, B.; Zhu, E.; Tsai, D. E.; Davids, M. S.; Brown, J. R.; Jurczak, W.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 48
• Page End: 49
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843480.04890.cc
• Languages: English
• ISSNs: 2572-9241